Results for: RXRX

Recursion Pharmaceuticals’ stock took a hit despite announcing positive safety data from its Phase 2 trial for REC-994, an investigational treatment for Cerebral Cavernous Malformation (CCM). While the trial met its primary endpoint for safety and tolerability, the company reported no significant improvements in patient outcomes at the 12-month mark. However, secondary endpoints showed encouraging trends in reduced lesion volume and hemosiderin ring size in patients on the highest dose.

On CNBC’s “Mad Money Lightning Round,” Jim Cramer recommended selling Petróleo Brasileiro S.A. – Petrobras (PBR) and buying Enterprise Products Partners L.P. (EPD), Recursion Pharmaceuticals, Inc. (RXRX), Casey’s General Stores, Inc. (CASY), and Broadcom Inc. (AVGO). Cramer called Cheniere Energy, Inc. (LNG) “terrific.” Price action: PBR rose 0.1%, EPD fell 0.3%, CASY fell 0.1%, RXRX rose 1.3%, LNG fell 1%, and AVGO gained 2%.